Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series

Journal of Clinical Pathology

Volumn 66, Issue 9, 2013, Pages 753-757

  Stotz, Michael ^a   Eisner, Florian ^a   Szkandera, Joanna ^a   Absenger, Gudrun ^a   Kornprat, Peter ^a   Lackner, Carolin ^a   Samonigg, Hellmut ^a   Gerger, Armin ^a   Pichler, Martin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE; TUMOR MARKER;

ACINAR CELL; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; EUROPE; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PARAMETERS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME; UNIVERSITY HOSPITAL;

NEUROENDOCRINE TUMOURS; PANCREATIC CANCER; SURGICAL PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; AGED; AUSTRIA; CA-19-9 ANTIGEN; CARCINOMA, ACINAR CELL; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84882957209     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201394     Document Type: Article

References (16)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Liszka L, Zielinska-Pajak E, Pajak J, et al. Colloid carcinoma of the pancreas: review of selected pathological and clinical aspects. Pathology 2008;40:655-63.
3. Austria S. Bauchspeicheldrüse (C25) -Krebsmortalität (Sterbefälle pro Jahr), Österreich ab 1983 2012 [updated 05.10.2012.]. http://www.statistik-oesterreich.at/web-de/statistiken/gesundheit/ krebserkrankungen/bauchspeicheldruese/index.html
4. David M, Lepage C, Jouve JL, et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 2009;101:215-18.
5. Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: An overview. J Gastrointest Oncol 2011;2:168-74.
6. Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 2003;33:3-14.
7. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1766-73.
8. Kloeppel G, Hruban RH, Longnecker DS, et al. Tumours of the exocrine pancreas. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000:219-51.
9. Sun C, Ansari D, Andersson R, et al. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012;18:4944-58.
10. Matos JM, Schmidt CM, Turrini O, et al. Pancreatic acinar cell carcinoma: A multi-institutional study. J Gastrointest Surg 2009;13:1495-502.
11. Schmidt CM, Matos JM, Bentrem DJ, et al. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg 2008;12:2078-86.
12. Kitagami H, Kondo S, HIrano S, et al. Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas 2007;35:42-6.
13. Hartwig W, Denneberg M, Bergmann F, et al. Acinar cell carcinoma of the pancreas: is resection justified even in limited metastatic disease? Am J Surg 2011;202:23-7.
14. Seki Y, Okusaka T, Ikeda M, et al. Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. Jpn J Clin Oncol. 2009;39:751-5.
15. Lowery MA, Klimstra DS, Shia J, et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist 2011;16:1714-20.
16. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84.